Valuation: BioNTech SE

Market Cap 21.38B 120B 23.97B 19.93B 18.12B 34.1B 2,321B 34.45B 239B 93.55B 1,181B 89.96B 88.04B 3,785B P/E 2026 *
-14.9x
P/E 2027 * -15.6x
Enterprise Value 10.01B 56.31B 11.23B 9.33B 8.48B 15.97B 1,087B 16.13B 112B 43.8B 553B 42.12B 41.22B 1,772B EV / Sales 2026 *
5.54x
EV / Sales 2027 * 6.27x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-3.80%
1 week-9.08%
Current month-9.68%
1 month-8.53%
3 months-4.47%
6 months-1.64%
Current year-12.16%
1 week 28.83
Extreme 28.83
32.01
1 month 28.83
Extreme 28.83
34.15
Current year 25.78
Extreme 25.78
41
1 year 25.78
Extreme 25.78
41
3 years 25.78
Extreme 25.78
49.05
5 years 25.78
Extreme 25.78
66.08
10 years 25.78
Extreme 25.78
66.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.80%-9.08% - - 23.93B
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.35%+303.95%+651.28% 43.05B
+0.30%-3.71%+28.89%+30.33% 42.48B
-3.82%-4.32%+2.49%+101.36% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-6.35%-13.20%-17.22% 23.93B
-1.24%-11.97%-38.10%+311.13% 22.22B
Average -4.18%-2.63%+38.26%+144.16% 42.9B
Weighted average by Cap. -4.80%-1.88%+44.70%+136.42%

Financials

2026 *2027 *
Net sales 1.81B 10.16B 2.03B 1.68B 1.53B 2.88B 196B 2.91B 20.2B 7.91B 99.85B 7.6B 7.44B 320B 1.81B 10.18B 2.03B 1.69B 1.53B 2.89B 197B 2.92B 20.24B 7.92B 100B 7.62B 7.46B 321B
Net income -1.38B -7.74B -1.54B -1.28B -1.17B -2.2B -149B -2.22B -15.39B -6.02B -76.08B -5.79B -5.67B -244B -1.31B -7.37B -1.47B -1.22B -1.11B -2.09B -142B -2.11B -14.66B -5.74B -72.45B -5.52B -5.4B -232B
Net Debt -11.37B -63.95B -12.75B -10.6B -9.63B -18.13B -1,234B -18.32B -127B -49.75B -628B -47.84B -46.81B -2,013B -10.03B -56.41B -11.24B -9.35B -8.5B -15.99B -1,089B -16.16B -112B -43.88B -554B -42.2B -41.29B -1,775B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
07/10/26 BRL 29.97 +0.81% 3,043
06/10/26 BRL 29.73 -3.00% 670
05/10/26 BRL 30.65 -2.98% 969
02/10/26 BRL 31.59 -0.38% 3,959
01/10/26 BRL 31.71 -0.66% 2,215
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
85.11EUR
Average target price
103.57EUR
Spread / Average Target
+21.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE